V
Vic E. Myer
Researcher at Novartis
Publications - 39
Citations - 15658
Vic E. Myer is an academic researcher from Novartis. The author has contributed to research in topics: Genome editing & Cas9. The author has an hindex of 24, co-authored 39 publications receiving 13226 citations. Previous affiliations of Vic E. Myer include Yale University & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +65 more
TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.
Journal ArticleDOI
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih Min A Huang,Yuji Mishina,Shanming Liu,Atwood K. Cheung,Frank Stegmeier,Gregory A. Michaud,Olga Charlat,Elizabeth Wiellette,Yue Zhang,Stephanie Wiessner,Marc Hild,Xiaoying Shi,Christine D. Wilson,Craig Mickanin,Vic E. Myer,Aleem Fazal,Ronald Tomlinson,Fabrizio C. Serluca,Wenlin Shao,Hong Cheng,Michael Shultz,Christina Rau,Markus Schirle,Judith Schlegl,Sonja Ghidelli,Stephen Fawell,Chris Lu,Daniel Curtis,Marc W. Kirschner,Christoph Lengauer,Peter Finan,John A. Tallarico,Tewis Bouwmeester,Jeffery A. Porter,Andreas Bauer,Feng Cong +35 more
TL;DR: This study uses a chemical genetic screen to identify a small molecule, XAV939, which selectively inhibits β-catenin-mediated transcription and reveals new mechanistic insights into the regulation of axin protein homeostasis, which presents new avenues for targeted Wnt pathway therapies.
Journal ArticleDOI
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Paul Nicklin,Philip Bergman,Bailin Zhang,Ellen Triantafellow,Henry Wang,Beat Nyfeler,Haidi Yang,Marc Hild,Charles Kung,Christine D. Wilson,Vic E. Myer,Jeffrey P. MacKeigan,Jeffrey A. Porter,Y. Karen Wang,Lewis C. Cantley,Peter Finan,Leon Murphy +16 more
TL;DR: It is shown that cellular uptake of L-glutamine and its subsequent rapid efflux in the presence of essential amino acids (EAA) is the rate-limiting step that activates mTOR.
Journal ArticleDOI
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen,Jesse S. Boehm,So Young Kim,Sapana R. Thomas,Sapana R. Thomas,Leslie Wardwell,Laura A. Johnson,Laura A. Johnson,Caroline Emery,Nicolas Stransky,Alexandria P. Cogdill,Jordi Barretina,Jordi Barretina,Giordano Caponigro,Haley Hieronymus,Haley Hieronymus,Haley Hieronymus,Ryan R. Murray,Kourosh Salehi-Ashtiani,David E. Hill,Marc Vidal,Jean J. Zhao,Xiaoping Yang,Ozan Alkan,Sungjoon Kim,Jennifer L. Harris,Christine D. Wilson,Vic E. Myer,Peter Finan,David E. Root,Thomas M. Roberts,Todd R. Golub,Todd R. Golub,Keith T. Flaherty,Reinhard Dummer,Barbara L. Weber,William R. Sellers,Robert Schlegel,Jennifer A. Wargo,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway +42 more
TL;DR: Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
Journal ArticleDOI
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.